The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …

PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Oral mucositis (OM) is a common, highly symptomatic complication of cancer therapy that
affects patients' function, quality of life, and ability to tolerate treatment. In certain patients …

Targeting checkpoints of immune cell activation has been demonstrated to be the most
effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte …

The treatment of cancer patients with immune checkpoint inhibitors (ICI)(anti-CTLA-4, anti-
PD-1, anti-PD-L1, combined therapy anti-PD-1/PD-L1 with anti-CTLA-4) has without doubt …

In primary Sjögren syndrome (pSS), the function of the salivary glands is often considerably
reduced. Multiple innate immune pathways are likely dysregulated in the salivary gland …

Purpose To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events in patients treated with …

Background Immune checkpoint inhibitor (ICI) monoclonal antibodies (mAbs) targeting
cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) or its …